Human | ATAD3B | 83858 | ATPase family, AAA domain containing 3B | These results demonstrate the potential for ATAD 3B as a putative marker in discriminating astrocytomas from oligodendrogliomas |
Human | PARVG | 64098 | parvin, gamma | INI1hSNF5 and PARVG do not seem to be the tumor suppressor genes involved in oligodendroglioma development and progression |
Human | MIB1 | 57534 | mindbomb E3 ubiquitin protein ligase 1 | Comparative genomic hybridization and immunohistochemical assessment of EGFR, PTEN, p53, and MIB-1 expression in 13 oligodendrogliomas, one oligoastrocytoma and 23 high-grade astrocytomas is reported |
Human | RTN4 | 57142 | reticulon 4 | Nogo-a expression in glial CNS tumors may be a marker to differentiate between oligodendrogliomas and other gliomas |
Human | AJAP1 | 55966 | adherens junctions associated protein 1 | While a mutation was not detected in the coding region of the SHREW1 gene in oligodendrogliomas, SHREW1 expression restoration resulted in suppression of cell adhesion and migration, thus, SHREW1 inactivation may lead to oligodendroglial tumorigenesis |
Human | ATAD3A | 55210 | ATPase family, AAA domain containing 3A | We also have shown that the loss of ATAD 3A/3B may be involved in the transformation pathway and the chemosensitivity of oligodendrogliomas |
Human | GLTSCR1 | 29998 | glioma tumor suppressor candidate region gene 1 | Polymorphisms in GLTSCR1 are associated with the development of oligodendrogliomas |
Human | OLIG2 | 10215 | oligodendrocyte lineage transcription factor 2 | Overexpression of OLIG2 was not only found in oligodendroglioma samples and normal neural tissue but also in a wide spectrum of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer cell lines |
Human | PRDX6 | 9588 | peroxiredoxin 6 | overexpression of peroxiredoxin 6 is associated with oligodendroglioma |
Human | SMARCB1 | 6598 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 | INI1hSNF5 and PARVG do not seem to be the tumor suppressor genes involved in oligodendroglioma development and progression |
Human | PTPRZ1 | 5803 | protein tyrosine phosphatase, receptor-type, Z polypeptide 1 | results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker |
Human | PTGS2 | 5743 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Immunohistochemical results are compared with patient survival in order to verify COX-2 prognostic significance in 32 primary oligodendrogliomas |
Human | PMS2 | 5395 | PMS2 postmeiotic segregation increased 2 (S. cerevisiae) | |
Human | NOTCH2 | 4853 | notch 2 | Results suggest that the NOTCH2 gene is not physically rearranged by t(1;19) translocation of oligodendroglioma tumors, and that the t(1;19) translocation arises from complex intra and interchromosomal rearrangements |
Human | MSH2 | 4436 | mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) | |
Human | MLH1 | 4292 | mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) | |
Human | KCNA5 | 3741 | potassium voltage-gated channel, shaker-related subfamily, member 5 | Kv1.5 potassium channel mRNA expression correlates with glioma entities and malignancy grades; expression is high in astrocytomas, moderate in oligodendrogliomas, and low in glioblastomas |
Human | IDH1 | 3417 | isocitrate dehydrogenase 1 (NADP+), soluble | Data show that the very high frequency of IDH1 mutations occurrs in diffuse astrocytomas, oligodendrogliomas, oligoastrocytomas and secondary glioblastomas |
Human | MSH6 | 2956 | mutS homolog 6 (E. coli) | |
Human | ERCC2 | 2068 | excision repair cross-complementing rodent repair deficiency, complementation group 2 | Polymorphisms in ERCC2 are associated with the development of oligodendrogliomas |
Human | EDNRB | 1910 | endothelin receptor type B | These data point to ET-1 as a possible survival factor for oligodendrogliomas via ET(B)-R activation and suggest that ET(B)-R-specific antagonists might constitute a potential therapeutic alternative for oligodendrogliomas |
Human | DFFB | 1677 | DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase) | DFFB haploinsufficiency from 1p allelic loss is a contributing factor in oligodendroglioma development |
Human | CDKN2A | 1029 | cyclin-dependent kinase inhibitor 2A | Title:Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.|Association:Y|Conclusion:Not Found |
Human | CD44 | 960 | CD44 molecule (Indian blood group) | expressed by cells of the oligodendrocyte lineage in vitro and by oligodendrogliomas in vivo; could play a role in migration of tumor cells in oligodendrocytic tumors |
Human | ARHGDIA | 396 | Rho GDP dissociation inhibitor (GDI) alpha | Underexpression of rho GDP dissociation inhibitor alpha is associated with oligodendroglioma |